Wallace M B, Warren S G, Bates M C, Robinson P A
Robert C. Byrd Health Sciences Center, West Virginia University, Charleston Division, USA.
W V Med J. 1995 Feb;91(2):50-3.
After one year of treatment, low-dose (20 mg/d) lovastatin achieved continued efficacy without tachyphylaxis in 36 patients with Type IIa or IIb hyperlipoproteinemia. Six week and one year reductions in low density lipoprotein (LDL) cholesterol were significant at 33% and 31% in these patients respectively; reductions in total cholesterol were also significant at 25% and 22% respectively. Increases in high density lipoprotein cholesterol (HDL) were 6% at six weeks and 10% at one year; triglycerides were reduced 16% and 11% respectively. The cholesterol lowering effects were similar for males and females (23% and 21% respectively). Low-dose lovastatin (20 mg/d) is a good choice for reducing cholesterol in patients with primary Type IIa or IIb hyperlipoproteinemia refractory to diet therapy because it is effective in lowering LDL-cholesterol, while raising HDL-cholesterol with few side effects and without tachyphylaxis.
经过一年的治疗，低剂量（20毫克/天）洛伐他汀在36例IIa型或IIb型高脂蛋白血症患者中持续有效且无快速耐受性。这些患者低密度脂蛋白（LDL）胆固醇在6周和1年时的降低幅度分别显著为33%和31%；总胆固醇的降低幅度也分别显著为25%和22%。高密度脂蛋白胆固醇（HDL）在6周时升高6%，1年时升高10%；甘油三酯分别降低16%和11%。男性和女性的胆固醇降低效果相似（分别为23%和21%）。低剂量洛伐他汀（20毫克/天）是饮食治疗无效的原发性IIa型或IIb型高脂蛋白血症患者降低胆固醇的良好选择，因为它能有效降低LDL胆固醇，同时升高HDL胆固醇，副作用少且无快速耐受性。
